



Minutes

MCW Institutional Biosafety Committee
Institutional Biosafety Committee
7/14/2026
1:00 pm
Zoom

1 Statements of Confidentiality and Conflicts of Interest

Quorum and Meeting Access: The Chair called the meeting to order at 1:01 pm and noted that the meeting was open to the public. Quorum existed at the start of the meeting with 10 voting members present. A quorum was maintained for the entire meeting.

Confidentiality: The Chair reminded the committee that while redacted meeting minutes will be made public, the information discussed should be considered confidential to protect the identity of individuals and the competitiveness of proprietary or technical information.

Conflict of Interest: The Chair asked the committee if any members needed to declare a conflict of interest with respect to any matter on the agenda. The Chair notified committee members that if they had a conflict of interest, they must leave the room during the final discussion and voting on that IBC submission.

2 Attendees

Committee Members Present

Lewis Bowen (Campus Operations)	Biological Safety Officer
Lezi E (Cell Biology Neurobiology and Anatomy)	R/SNA Technology Expert
Benjamin Gantner (Medicine)	Chair
Kunal Gupta (Neurosurgery)	R/SNA Technology Expert
Anna Huppler (Pediatrics)	R/SNA Technology Expert
Eric Jensen (Research Office)	Animal Containment Expert
Tyce Kearl (Medicine)	R/SNA Technology Expert
	HGT Expert
Angela Mathison (Surgery)	R/SNA Technology Expert
Laura Stephens (Non-MCW)	Non-Affiliated Member
Matthew Surdel (Medicine)	R/SNA Technology Expert

Committee Members Absent

Kenneth Allen (Research Office)	Alternate Animal Containment Expert, Non-Voting
---------------------------------	---

Nikki Lytle (Surgery)
 Sandy Montes-Gruber (Non-MCW)
 Qizhen Shi (Pediatrics)

R/SNA Technology Expert
 Non-Affiliated Member
 R/SNA Technology Expert

3 Meeting Minutes Reviewed at this Meeting

06/09/2026 (Zoom)

Motion:	Minutes Approved
Yes Votes:	10
No Votes:	0
Abstained:	0
Recused:	0
Total Votes:	10

4 New Business

1. IBC Membership Recommendations

The Chair notified the Institutional Biosafety Committee (IBC) members that there will be openings for new members in the near future. He requested that current IBC members contact him or the IBC Office if they know of anyone that would be interested in serving on the IBC.

2. Hazard Communication Forms

◦ Proposed revisions

The Chair notified the Institutional Biosafety Committee (IBC) that many amendments submitted for clinical trials that require Hazard Communication forms are to update room locations where the investigational product is used and noted that there was an opportunity to make the form more flexible. The Chair asked the Biological Safety Officer (BSO) to present the proposed revisions to the form. These changes include the removal of agent storage, disposal locations, specific room numbers, and transport routes; these changes would allow Froedtert and the study teams greater flexibility while not impacting safety. The goal would be to include the type of rooms that would be appropriate for the work, as opposed to specific room numbers. Froedtert's Office of Clinical Research and Innovative Care Compliance (OCRICC) would then be able to confirm that the work is being done in the appropriate locations within Froedtert. After discussion, the Committee voted to allow for greater flexibility in the Hazard Communication forms. The Biosafety Office will work with OCRICC to make the necessary changes.

◦ HGT vs. Non-HGT Studies

The Chair continued the discussion about the Hazard Communication forms and reminded the Institutional Biosafety Committee (IBC) that Hazard Communication forms are currently only required for clinical trials that involve human gene transfer (HGT). Since the inception of the Hazard Communication form, there have been several non-HGT studies that have submitted these forms with their IBC Applications due to the nature of the studies. The Chair asked the IBC if the requirement for Hazard Communication forms should officially be extended to non-HGT clinical studies (clinical trials that don't involve the use of recombinant DNA). A Committee member noted that non-recombinant human cell products require Biosafety Level (BSL)2 precautions, which are standard, so there is no practical change in risk or precautions for the administration of such products. A representative from the Office of Clinical Research and Innovative Care Compliance (OCRICC) noted that the Hazard Communication forms are beneficial when providing guidance for procedures that are not the standard, such as when additional personal protective equipment (PPE) is required or when individuals with certain risk factors should not be present during preparation or administration of the product. After discussion, the Committee determined that further information would need to be gathered from nursing and pharmacy staff in Froedtert to determine whether Hazard Communication forms would be useful for non-HGT studies before being brought

back to an IBC Meeting for further discussion. The IBC voted to continue to request Hazard Communication forms for non-HGT studies, as has been the unofficial practice, until the Committee makes an official determination.

The third New Business Item was discussed after application reviews.

3. IBC Continuing Education (CE) – IBC Review Data

The Chair shared data and graphs with the Institutional Biosafety Committee that showed the trend in review times from March 2025 through March 2026. Over that period of time the average review time had decreased, while the numbers of applications had increased. He commended the Committee and the Biosafety Office on their hard work and thanked them for their efforts.

4. Administrative Report

The Chair asked the Committee Members to review the Administrative Report and then invited discussion. No concerns were raised.

5. Exempt Rodent Report

The Exempt Rodent Report was provided to the Committee members.

5	Application Reviews
IBC20190014_AME08	Grobe Lab IBC Application Principal Investigator: Justin Grobe Motion: Decision Pending Changes Yes Votes: 10 No Votes: 0 Abstained: 0 Recused: 0 Total Votes: 10 NIH Guidelines: Section III-D-1, Section III-D-3, Section III-D-4, Section III-E, Section III-F-1, Section III-F-8 (C-I), Section III-F-8 (C-II), Section III-F-8 (C-VII), Section III-F-8 (C-VIII) Biosafety Level(s): BSL1, BSL2
Deliberations:	The Chair introduced this amendment of an Institutional Biosafety Committee (IBC) application and the Primary Reviewer elaborated on the study. The Principal Investigator (PI) wishes to include mouse tumor cell engraftment procedures. Immortal mouse cell lines will be cultured and injected into recipient mouse pancreas to study the changes in energy expenditure and cachexia in the animal model. The Primary and Secondary Reviewers stated that risk assessment and mitigation strategies are appropriate. The Reviewers requested that the PI provide additional detail regarding the experiments with the new mouse pancreatic cell lines before and after engraftment, and to clarify where the cells will be administered to the mice. The Biological Safety Officer (BSO) noted that someone with shipping as a responsibility will need to complete training for shipping exempt human and animal specimens. The Animal Containment Expert (ACE) had no additional concerns. After brief discussion, upon a motion duly made by the Primary Reviewer and seconded, the Committee voted to approve this amendment pending the requested changes.

6**Adjournment**

There being no further business, the meeting was adjourned at 2:34 pm. The next regularly scheduled meeting will be held on Tuesday, August 11, 2026 at 1:00 pm in Zoom.